MODIFY I/II
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 2,655 patients receiving antibiotics for Clostridium difficile infection, a single dose of bezlotoxumab reduced recurrent CDI at 12 weeks compared with placebo.
N
2 655
Schéma
Two double-blind RCTs (pooled)
Critère
Recurrent CDI at 12 weeks
Pertinence
3
RésultatRecurrence 17 % vs 28 % (MODIFY I) and 16 % vs 26 % (MODIFY II); ARR ~10 pp; NNT ≈ 10.
Wilcox MH, et al. N Engl J Med. 2017;376(4):305-317. 10.1056/NEJMoa1602615
Discussion et critique
Bezlotoxumab as adjunctive recurrence prevention — most useful in patients ≥65 years, immunocompromised or with severe or repeated CDI.